Annas Al-Sharea1, Andrew J Murphy2, L A Huggins3, Y Hu3, Ira J Goldberg3, Prabhakara R Nagareddy4. 1. Baker Heart and Diabetes Institute, Melbourne, Australia. 2. Division of Preventive Medicine and Nutrition, Department of Medicine, Columbia University, New York, USA; Baker Heart and Diabetes Institute, Melbourne, Australia. 3. Division of Preventive Medicine and Nutrition, Department of Medicine, Columbia University, New York, USA; Dept. of Medicine, New York University, New York, USA. 4. Division of Preventive Medicine and Nutrition, Department of Medicine, Columbia University, New York, USA; Dept. of Nutrition Sciences, University of Alabama at Birmingham, USA. Electronic address: pnreddy@uab.edu.
Abstract
BACKGROUND AND AIMS: Leukocytosis, particularly monocytosis, has been shown to promote atherosclerosis in both diabetic and non-diabetic mouse models. We previously showed that hyperglycemia independently promotes monocytosis and impairs the resolution of atherosclerosis. Since patients with chronic diabetes often develop dyslipidemia and also have increased risk for atherosclerosis, we sought to examine how controlling blood glucose affects atherosclerosis development in the presence of severe hyperlipidemia. METHODS: Diabetes was induced using streptozotocin (STZ) in low density lipoprotein receptor (Ldlr) knockout (Ldlr-/-) mice after which they were fed a high-cholesterol diet for 4 weeks. Control and diabetic mice were treated with vehicle or sodium glucose cotransporter inhibitor (SGLT2i, Phlorizin or Dapagliflozin) for the duration of the diet. RESULTS: Induction of diabetes resulted in a dramatic increase in plasma cholesterol (TC) and triglyceride (TG) levels. These mice also exhibited an increased number of circulating monocytes and neutrophils. Monocytosis was driven by increased proliferation of progenitor cells in the bone marrow. Tighter glycemic control by SGLT2i treatment not only reduced monocytosis and atherosclerosis but also improved plasma lipoprotein profile. Interestingly, improved lipoprotein profile was not due to decreased TG synthesis or clearance via low density lipoprotein receptor-related protein (Lrp) 1 or scavenger receptor class B member (Scarb1) pathways, but likely mediated by heparin sulfate proteoglycans (HSPG)-dependent clearance mechanisms in the liver. Further examination of the liver revealed an important role for bile acid transporters (Abcg5, Abcg8) and cytochrome P450 enzymes in the clearance of hepatic cholesterol. CONCLUSIONS: These data suggest that tighter glycemic control in diabetes can improve lipoprotein clearance exclusive of Ldlr, likely via HSPG and bile acid pathways, and has an overall net positive effect on atherosclerosis.
BACKGROUND AND AIMS: Leukocytosis, particularly monocytosis, has been shown to promote atherosclerosis in both diabetic and non-diabeticmouse models. We previously showed that hyperglycemia independently promotes monocytosis and impairs the resolution of atherosclerosis. Since patients with chronic diabetes often develop dyslipidemia and also have increased risk for atherosclerosis, we sought to examine how controlling blood glucose affects atherosclerosis development in the presence of severe hyperlipidemia. METHODS:Diabetes was induced using streptozotocin (STZ) in low density lipoprotein receptor (Ldlr) knockout (Ldlr-/-) mice after which they were fed a high-cholesterol diet for 4 weeks. Control and diabeticmice were treated with vehicle or sodiumglucose cotransporter inhibitor (SGLT2i, Phlorizin or Dapagliflozin) for the duration of the diet. RESULTS: Induction of diabetes resulted in a dramatic increase in plasma cholesterol (TC) and triglyceride (TG) levels. These mice also exhibited an increased number of circulating monocytes and neutrophils. Monocytosis was driven by increased proliferation of progenitor cells in the bone marrow. Tighter glycemic control by SGLT2i treatment not only reduced monocytosis and atherosclerosis but also improved plasma lipoprotein profile. Interestingly, improved lipoprotein profile was not due to decreased TG synthesis or clearance via low density lipoprotein receptor-related protein (Lrp) 1 or scavenger receptor class B member (Scarb1) pathways, but likely mediated by heparin sulfate proteoglycans (HSPG)-dependent clearance mechanisms in the liver. Further examination of the liver revealed an important role for bile acid transporters (Abcg5, Abcg8) and cytochrome P450 enzymes in the clearance of hepatic cholesterol. CONCLUSIONS: These data suggest that tighter glycemic control in diabetes can improve lipoprotein clearance exclusive of Ldlr, likely via HSPG and bile acid pathways, and has an overall net positive effect on atherosclerosis.
Authors: Tiangang Li; Jessica M Francl; Shannon Boehme; Adrian Ochoa; Youcai Zhang; Curtis D Klaassen; Sandra K Erickson; John Y L Chiang Journal: J Biol Chem Date: 2011-12-05 Impact factor: 5.157
Authors: Kevin Jon Williams; Ming-Lin Liu; Yanqing Zhu; Xiangsheng Xu; William R Davidson; Peter McCue; Kumar Sharma Journal: Diabetes Date: 2005-04 Impact factor: 9.461
Authors: Loredana G Bucciarelli; Thoralf Wendt; Wu Qu; Yan Lu; Evanthia Lalla; Ling Ling Rong; Mouza T Goova; Bernhard Moser; Thomas Kislinger; Daniel C Lee; Yogita Kashyap; David M Stern; Ann Marie Schmidt Journal: Circulation Date: 2002-11-26 Impact factor: 29.690
Authors: Stephane Potteaux; Emmanuel L Gautier; Susan B Hutchison; Nico van Rooijen; Daniel J Rader; Michael J Thomas; Mary G Sorci-Thomas; Gwendalyn J Randolph Journal: J Clin Invest Date: 2011-04-18 Impact factor: 14.808
Authors: Maria F Lopes-Virella; Michael Brent McHenry; Stuart Lipsitz; Eunsil Yim; Peter F Wilson; Daniel T Lackland; Timothy Lyons; Alicia J Jenkins; Gabriel Virella Journal: Atherosclerosis Date: 2006-03-10 Impact factor: 5.162
Authors: Erin M Foley; Philip L S M Gordts; Kristin I Stanford; Jon C Gonzales; Roger Lawrence; Nicole Stoddard; Jeffrey D Esko Journal: Arterioscler Thromb Vasc Biol Date: 2013-07-11 Impact factor: 8.311
Authors: Fredrik Johansson; Farah Kramer; Shelley Barnhart; Jenny E Kanter; Tomas Vaisar; Rachel D Merrill; Linda Geng; Kazuhiro Oka; Lawrence Chan; Alan Chait; Jay W Heinecke; Karin E Bornfeldt Journal: Proc Natl Acad Sci U S A Date: 2008-02-05 Impact factor: 11.205
Authors: Saj Parathath; Lisa Grauer; Li-Shin Huang; Marie Sanson; Emilie Distel; Ira J Goldberg; Edward A Fisher Journal: Diabetes Date: 2011-05-11 Impact factor: 9.461
Authors: Michelle C Flynn; Michael J Kraakman; Christos Tikellis; Man K S Lee; Nordin M J Hanssen; Helene L Kammoun; Raelene J Pickering; Dragana Dragoljevic; Annas Al-Sharea; Tessa J Barrett; Fiona Hortle; Frances L Byrne; Ellen Olzomer; Domenica A McCarthy; Casper G Schalkwijk; Josephine M Forbes; Kyle Hoehn; Liza Makowski; Graeme I Lancaster; Assam El-Osta; Edward A Fisher; Ira J Goldberg; Mark E Cooper; Prabhakara R Nagareddy; Merlin C Thomas; Andrew J Murphy Journal: Circ Res Date: 2020-06-22 Impact factor: 17.367
Authors: Ivana Semova; Amy E Levenson; Joanna Krawczyk; Kevin Bullock; Mary E Gearing; Alisha V Ling; Kathryn A Williams; Ji Miao; Stuart S Adamson; Dong-Ju Shin; Satyapal Chahar; Mark J Graham; Rosanne M Crooke; Lee R Hagey; David Vicent; Sarah D de Ferranti; Srividya Kidambi; Clary B Clish; Sudha B Biddinger Journal: Circulation Date: 2022-02-23 Impact factor: 39.918
Authors: Enrico Longato; Barbara Di Camillo; Giovanni Sparacino; Lorenzo Gubian; Angelo Avogaro; Gian Paolo Fadini Journal: BMJ Open Diabetes Res Care Date: 2020-06